Not available
Quote | Dare Bioscience Inc. (NASDAQ:DARE)
Last: | $3.09 |
---|---|
Change Percent: | 7.44% |
Open: | $3.36 |
Close: | $3.09 |
High: | $3.44 |
Low: | $3.05 |
Volume: | 86,738 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Dare Bioscience Inc. (NASDAQ:DARE)
2024-07-01 09:02:05 ET Dare Bioscience Inc (DARE) announced stock split at a ratio of 1-for-12 on 2024-07-01 ... Full story available on KlickAnalytics.com
2024-06-27 08:28:44 ET More on Dare Bioscience Brookline Capital upgrades Dare Bioscience, cites improved funding Dare Bioscience GAAP EPS of -$0.07 Read the full article on Seeking Alpha For further details see: Daré Bioscience announces reverse sto...
Message Board Posts | Dare Bioscience Inc. (NASDAQ:DARE)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $DARE News Article - Dar Bioscience to Participate in Xpectives.Health SUMMIT Innovatio | whytestocks | investorshangout | 04/17/2023 12:45:50 PM |
whytestocks: $DARE News Article - Dar Bioscience Reports Full Year 2022 Financial Results and Provid | whytestocks | investorshangout | 03/30/2023 4:50:50 PM |
whytestocks: $DARE News Article - Dar Bioscience to Present at the 35th Annual Roth Conference | whytestocks | investorshangout | 03/01/2023 6:25:47 PM |
Might be a runner in due time | harry crumb | investorshub | 02/02/2023 11:12:12 AM |
The $DARE train has not even left the | nonsequetor | investorshub | 01/26/2023 10:11:07 PM |
News, Short Squeeze, Breakout and More Instantly...
2024-07-01 09:02:05 ET Dare Bioscience Inc (DARE) announced stock split at a ratio of 1-for-12 on 2024-07-01 ... Full story available on KlickAnalytics.com
Shares Expected to Begin Trading on Split-Adjusted Basis on July 1, 2024 SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today announced that it will implement a 1-for-12 reverse split...
Phase 2b study demonstrated topical Sildenafil Cream, 3.6% improved outcomes among women with female sexual arousal disorder (FSAD), particularly in an exploratory subset of women with FSAD with or without concomitant decreased desire There are currently no FDA-approved therapies fo...